Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OKYO NASDAQ:SIGA NASDAQ:SVRA NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOKYOOKYO Pharma$3.27+3.5%$2.61$0.85▼$3.35$122.99M-0.09208,320 shs99,010 shsSIGASiga Technologies$8.96+4.8%$6.67$4.95▼$12.83$641.59M0.94439,005 shs831,891 shsSVRASavara$2.64+0.4%$2.35$1.89▼$4.70$456.29M0.4894,571 shs433,988 shsUPXIUpexi$6.04+8.4%$6.95$1.90▼$22.57$539.75M-0.5212.53 million shs11.87 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOKYOOKYO Pharma0.00%+5.48%+14.34%+125.52%+227.00%SIGASiga Technologies0.00%+38.70%+29.86%+58.30%+2.99%SVRASavara0.00%+1.93%+14.78%-7.69%-34.00%UPXIUpexi0.00%+31.30%+20.80%-38.80%+33.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOKYOOKYO Pharma2.6952 of 5 stars3.55.00.00.01.71.70.0SIGASiga Technologies2.0254 of 5 stars0.02.00.00.02.50.83.1SVRASavara1.8291 of 5 stars3.30.00.00.01.43.30.6UPXIUpexi3.5934 of 5 stars3.55.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOKYOOKYO Pharma 3.00Buy$7.00114.07% UpsideSIGASiga Technologies 0.00N/AN/AN/ASVRASavara 2.60Moderate Buy$5.60112.12% UpsideUPXIUpexi 3.00Buy$15.50156.62% UpsideCurrent Analyst Ratings BreakdownLatest OKYO, SIGA, UPXI, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/4/2025UPXIUpexiAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.006/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.005/29/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$6.00 ➝ $2.005/28/2025SVRASavaraEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.005/28/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $8.005/28/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/ASIGASiga Technologies$138.72M4.63$0.84 per share10.71$2.92 per share3.07SVRASavaraN/AN/AN/AN/A$1.00 per shareN/AUPXIUpexi$26M20.76N/AN/A$6.24 per share0.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)SIGASiga Technologies$59.21M$1.137.937.17N/A45.73%40.52%35.62%N/ASVRASavara-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest OKYO, SIGA, UPXI, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025SVRASavara-$0.12N/AN/AN/AN/AN/A8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 million5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/13/2025Q1 2025SVRASavara-$0.12-$0.12N/A-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOKYOOKYO PharmaN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOKYOOKYO PharmaN/A0.400.40SIGASiga TechnologiesN/A10.096.28SVRASavara0.2014.9114.91UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOKYOOKYO Pharma2.97%SIGASiga Technologies55.40%SVRASavara87.93%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipOKYOOKYO Pharma40.46%SIGASiga Technologies1.95%SVRASavara5.33%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOKYOOKYO Pharma737.61 million22.39 millionNot OptionableSIGASiga Technologies4071.61 million70.21 millionOptionableSVRASavara20172.84 million163.63 millionOptionableUPXIUpexi13089.36 million61.12 millionOptionableOKYO, SIGA, UPXI, and SVRA HeadlinesRecent News About These CompaniesUpexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What HappenedAugust 9 at 1:00 PM | marketbeat.comCrypto Currents: SEC eases staking rules as bitcoin miners pivot to AIAugust 6, 2025 | msn.comAlliance Global Partners Begins Coverage on Upexi (NASDAQ:UPXI)August 6, 2025 | americanbankingnews.comUpexi Surpasses 2 Million SOL in its TreasuryAugust 5, 2025 | taiwannews.com.twTSolana Treasury Company Upexi Surpasses 2M in SOL HoldingsAugust 5, 2025 | coindesk.comUpexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global PartnersAugust 5, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 SharesJuly 31, 2025 | marketbeat.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of StockJuly 31, 2025 | insidertrades.comUpexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?July 31, 2025 | marketbeat.comUpexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14thJuly 30, 2025 | manilatimes.netMUpexi Secures $500M Equity Deal to Buy More Solana Despite Stock DropJuly 30, 2025 | thecurrencyanalytics.comTUpexi enters $500M equity line agreementJuly 29, 2025 | msn.comUpexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury StrategyJuly 29, 2025 | manilatimes.netMSolana Treasury firm Upexi secures $500M to acquire more SOLJuly 29, 2025 | msn.comUpexi (NASDAQ:UPXI) Shares Gap Up - Here's WhyJuly 28, 2025 | marketbeat.comTraders Buy Large Volume of Call Options on Upexi (NASDAQ:UPXI)July 28, 2025 | marketbeat.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of StockJuly 25, 2025 | marketbeat.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Purchases 11,000 Shares of StockJuly 25, 2025 | marketbeat.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) CEO Buys 161,943 Shares of StockJuly 25, 2025 | marketbeat.comUpexi: The Market Loves Crypto Treasury CompaniesJuly 25, 2025 | seekingalpha.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of StockJuly 25, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOKYO, SIGA, UPXI, and SVRA Company DescriptionsOKYO Pharma NASDAQ:OKYO$3.27 +0.11 (+3.48%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.18 -0.09 (-2.60%) As of 08/8/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Siga Technologies NASDAQ:SIGA$8.96 +0.41 (+4.80%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$8.95 -0.01 (-0.11%) As of 08/8/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Savara NASDAQ:SVRA$2.64 +0.01 (+0.38%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.50 -0.14 (-5.27%) As of 08/8/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Upexi NASDAQ:UPXI$6.04 +0.47 (+8.44%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.20 +0.16 (+2.65%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
